Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryFreshfields and Hengeler take European SpaceX mandates as US IPO taps EU retail investors for first timeLaw firmsWill Lewallen11 Jun 2026Slaughters and Ropes among line-up on GSK’s $10.6bn US cancer drug firm acquisitionLaw firmsTheresa Hargreaves11 Jun 2026Latham, Kirkland and Simpson Thacher top for tier 1 rankings in new L500 US researchLaw firm dataAlex Ryan10 Jun 2026Bakers’ outgoing London chief on why the firm is doubling down on transactions in the CityLaw firmsTom Cox17 Jun 2026Top US duo tune in as Fox makes $22bn streaming acquisitionLaw firmsKate Peacock15 Jun 2026‘We’re down to earth, we’re fair, we’re ambitious’ – Browne Jacobson hits record £148.8m turnoverLaw firmsTom Cox15 Jun 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025